Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Authors:

Abstract
Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn’s disease (CD) naïve to immunosuppressants and biologics using a UK public payer perspective. Design A regression model estimated weekly CD Activity Index (CDAI)-based transition matrices (remission: CDAI Results Over 48 weeks, TC was associated with a higher clinical remission (CDAI Conclusion A TC strategy as used in the CALM trial is cost-effective compared with CM. Incorporating costs related to work productivity increases the economic value of TC. Cross-national inferences from this analysis should be made with caution given differences in healthcare systems. Trial registration number NCT01235689; Results.
Funding Information
  • AbbVie

This publication has 25 references indexed in Scilit: